Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06039085 · ClinicalTrials.gov registry record
Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment
A clinical trial of Prostate Cancer, sponsored by Ryan J. Halter.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06039085 is a study of Prostate Cancer that is actively recruiting participants, run by Ryan J. Halter. The registered enrollment target is 200 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06039085, a study of Prostate Cancer, is actively recruiting participants, sponsored by Ryan J. Halter.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This research will study a custom device developed to detect if any prostate cancer tissue is left behind when the prostate is removed. This device is called an Electrical Impedance Imaging (EII) probe.
Conditions Studied
Interventions
- DEVICE custom device to demonstrate a significant difference in electrical impedance signatures
Study Locations (1)
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-11-03 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06039085
The ClinicalTrials.gov registry entry for NCT06039085 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Ryan J. Halter, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which custom device to demonstrate a significant difference in electrical impedance signatures is the first listed.
NCT06039085 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06039085 about?
NCT06039085 is a clinical study titled "Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment". This research will study a custom device developed to detect if any prostate cancer tissue is left behind when the prostate is removed. This device is called an Electrical Impedance Imaging (EII) probe.
What is the current status of trial NCT06039085?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-11-03. Estimated completion is 2027-12-31.
What conditions does trial NCT06039085 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT06039085?
The interventions under investigation include: custom device to demonstrate a significant difference in electrical impedance signatures (DEVICE).
Who is sponsoring clinical trial NCT06039085?
This trial is sponsored by Ryan J. Halter, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06039085 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.